Film-Coated Tablet without Deucravacitinib
Sponsors
Janssen - Cilag International
Conditions
Moderate to Severe Plaque Psoriasis
Phase 3
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis
RecruitingCTIS2023-505121-14-00
Start: 2024-01-18Target: 320Updated: 2025-11-25
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis
RecruitingCTIS2023-507039-39-00
Start: 2024-03-22Target: 392Updated: 2025-11-28